Key facts
- Vesalic’s last known valuation is $35.0M (Feb 2026).
- It has raised $6.3M; the latest was Angel (individual) ($2.5M) in Feb 2026.
- Notable investors include Bertrand Meunier, Elie Vannier, Oscar Schafer, Simon Black.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Vesalic
- ·The full record, as it builds
Funding rounds
No funding rounds for Vesalic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vesalic
Operator of a biotech company intended to focus on neurodegenerative diseases. The company has discovered a systemic process, largely external to the brain and central nervous system, that is suspected to be a pathogenic driver of ALS (Amyotrophic Lateral Sclerosis), enabling doctors aid the treatment and diagnosis of the disease, and potentially other neurodegenerative diseases, including Alzheimer's and Parkinson's.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2023
- Employees
- 5
- Website
- vesalic.com/
- Ownership
- Privately Held (backing)
Vesalic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vesalic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vesalic in its N-PORT filings yet. We sweep new filings monthly.